Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Vanessa B Vogensen *Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, Groningen, the Netherlands.
Sanjay Singh *Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
Christopher J AllendeTranslational Genomics Research Institute, Flagstaff, Arizona, USA.
David M EngelthalerTranslational Genomics Research Institute, Flagstaff, Arizona, USA.ORCID 0000-0001-5945-059X
Gunavanthi D BoorgulaDivision of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
Tania A ThomasDepartment of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Marieke G G SturkenboomDepartment of Clinical Pharmacy and Pharmacology, University Medical Centrum Groningen, University of Groningen, Groningen, the Netherlands.ORCID 0000-0002-3420-0591
Onno W AkkermanDepartment of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0001-5638-9260
Shashikant SrivastavaDivision of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.ORCID 0000-0002-8786-8851
Funding
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infectionR01AI131939 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGELTHALER, DAVID M, METCALFE, JOHN ZAPATA · 2018 to 2023
$3.9M
PK-PD of combination antituberculosis therapy for suppression of drug-resistanceR01AI079497 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GUMBO, TAWANDA · 2008 to 2011
$2.3M
PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TBR01HD099756 · NICHD · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI KANT, SHASHI · 2019 to 2023
$1.6M
Short course therapy for MDR-TB based on PK/PD answers for biological variabilityR56AI111985 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GUMBO, TAWANDA · 2014 to 2014
$900k
HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 1R01HD099756HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI131939HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R56 AI111985, R01AI079497NIAID NIH HHS R01 AI079497NIAID NIH HHS R01 AI131939NIAID NIH HHS R56 AI111985NICHD NIH HHS R01 HD099756University of Texas System (UT) STARS award #250439/39411
6 · The paper itself
Abstract
The impact of heteroresistance on tuberculosis (TB) treatment outcomes is unclear, as is the role of different rifampin and isoniazid exposures on developing resistance mutations. Hollow fiber system model of TB (HFS-TB) units were inoculated with drug-susceptible
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis. · full record | OpenQuestion